Back to search

Peptide record

TPDB43273

Anticancer modified_plain modified

6 amino acids

TPDB ID TPDB43273

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0 Peptipedia SATPdb dbACP

Sequence_Type

modified_plain

Has_Modification Yes

Description A 6-aa modified anticancer peptide sequence curated from CancerPPD 2.0, Peptipedia, SATPdb, and other sources, without an available 3D structural model.

Modification

Chemical: A* = Cα -dialkylated glycine (Aaa2,2 )

Sequence

YA*GFM

FASTA

>TPDB43273|Anticancer|length=6
YA*GFM

Formula C28H37N5O7S1

Absent Amino Acids RNDCEQHILKPSTWV

Common Amino Acids AGMFY

Mass 587.69

PI 5.94

Basic Residues 0

Acidic Residues 0

Hydrophobic Residues 4

Net Charge -0

Boman Index -2.46

Hydrophobicity 0.800

Aliphatic Index 16.67

Half Life

Mammalian: 2.8 hour Yeast: 10 min E.coli: 2 min

Extinction Coefficient Cystines 1490

Absorbance 280nm 253.53

Polar Residues 1

number

Amino Acid Distribution

A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 0 K: 0 M: 1 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0

Length

Formula

C28H37N5O7S1

Mass

587.69

5.94

Net Charge

-0

Boman Index

-2.46

Hydrophobicity

0.800

C_terminal_Modification

Free

Chemical_Modification

A* = Cα -dialkylated glycine (Aaa2,2 )

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antitumor

Origin

Synthetic Peptide

Evidence 1 Activity

Activity

Activity Raw

13.7% inhibition at 10-6M

Detail Source Activity Anticancer

Target

Cancer Type Larynx Cancer

Cell Line HEp-2

Tissue Affected Larynx

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Raw

25.8% inhibition at 10-5M

Detail Source Activity Anticancer

Target

Cancer Type Larynx Cancer

Cell Line HEp-2

Tissue Affected Larynx

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 3 Activity

Activity

Activity Raw

34.7% inhibition at 10-4M

Detail Source Activity Anticancer

Target

Cancer Type Larynx Cancer

Cell Line HEp-2

Tissue Affected Larynx

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 4 Activity

Activity

Activity Raw

44.5% inhibition at 10-3M

Detail Source Activity Anticancer

Target

Cancer Type Larynx Cancer

Cell Line HEp-2

Tissue Affected Larynx

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 5 Activity

Activity

Activity Raw

8.5% inhibition at 10-6M

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 6 Activity

Activity

Activity Raw

9.5% inhibition at 10-5M

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 7 Activity

Activity

Activity Raw

15.4% inhibition at 10-4M

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 8 Activity

Activity

Activity Raw

24.1% inhibition at 10-3M

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 9 Activity

Activity

Activity Raw

2.4% inhibition at 10-6M

Detail Source Activity Anticancer

Target

Cancer Type Skin Cancer

Cell Line HBL

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 10 Activity

Activity

Activity Raw

4.5% inhibition at 10-5M

Detail Source Activity Anticancer

Target

Cancer Type Skin Cancer

Cell Line HBL

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 11 Activity

Activity

Activity Raw

11.4% inhibition at 10-4M

Detail Source Activity Anticancer

Target

Cancer Type Skin Cancer

Cell Line HBL

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 12 Activity

Activity

Activity Raw

23.2% inhibition at 10-3M

Detail Source Activity Anticancer

Target

Cancer Type Skin Cancer

Cell Line HBL

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 13 Activity

Activity

Activity Raw

16.2% inhibition at 10-6M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 14 Activity

Activity

Activity Raw

6.6% inhibition at 10-5M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 15 Activity

Activity

Activity Raw

5.1% inhibition at 10-4M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 16 Activity

Activity

Activity Raw

14.5% inhibition at 10-3M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 17 Activity

Activity

Activity Raw

26.4% inhibition at 10-6M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line SW-620

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 18 Activity

Activity

Activity Raw

13.1% inhibition at 10-5M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line SW-620

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 19 Activity

Activity

Activity Raw

14.6% inhibition at 10-4M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line SW-620

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 20 Activity

Activity

Activity Raw

38.4% inhibition at 10-3M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line SW-620

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 21 Activity

Activity

Activity Raw

17.7% inhibition at 10-6M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line CaCo-2

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 22 Activity

Activity

Activity Raw

10.9% inhibition at 10-5M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line CaCo-2

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 23 Activity

Activity

Activity Raw

12.1% inhibition at 10-4M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line CaCo-2

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 24 Activity

Activity

Activity Raw

8.1% inhibition at 10-3M

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line CaCo-2

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 25 Activity

Activity

Activity Raw

9.6% inhibition at 10-4M

Detail Source Activity Anticancer

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006

Evidence 26 Activity

Activity

Activity Raw

29.9% inhibition at 10-3M

Detail Source Activity Anticancer

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 23.03-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2006